NO990471L - Farmasoeytisk sammensetning av pinnsvinproteiner og anvendelse derav - Google Patents

Farmasoeytisk sammensetning av pinnsvinproteiner og anvendelse derav

Info

Publication number
NO990471L
NO990471L NO990471A NO990471A NO990471L NO 990471 L NO990471 L NO 990471L NO 990471 A NO990471 A NO 990471A NO 990471 A NO990471 A NO 990471A NO 990471 L NO990471 L NO 990471L
Authority
NO
Norway
Prior art keywords
carrier
hedgehog protein
pharmaceutical composition
hedgehog
binds
Prior art date
Application number
NO990471A
Other languages
English (en)
Other versions
NO990471D0 (no
Inventor
Kurt Lang
Apollon Papadimitriou
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of NO990471D0 publication Critical patent/NO990471D0/no
Publication of NO990471L publication Critical patent/NO990471L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Farmasøytisk sammensetning av et pinnsvinprotein,at pinnsvinproteinet er bundet til en hydrofil bærer hvilken er biokompatibel og biodegraderbar hvor bæreren er en polymer som binder pinnsvinproteinet som en negativt ladet. bærer som et resultat av ioniske interaksjoner, ikke denaturerer pinnsvinproteinet når det. binder til bæreren,. inneholder minst 0,1 til 2 negativt ladede. residuer per monomer under nøytrale betingelser, inneholder ladningen i formen av sure grupper, - har en gjennomsnittlige molekylvekten på minst 50.000 Da,. - og ikke inneholder agarose. reversibelt og aktivt frigjør pinnsvinproteiner in vivo fra en bærer på en forsinket måte.
NO990471A 1998-02-04 1999-02-01 Farmasoeytisk sammensetning av pinnsvinproteiner og anvendelse derav NO990471L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98101893 1998-02-04
EP98104416 1998-03-12

Publications (2)

Publication Number Publication Date
NO990471D0 NO990471D0 (no) 1999-02-01
NO990471L true NO990471L (no) 1999-08-05

Family

ID=26149005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990471A NO990471L (no) 1998-02-04 1999-02-01 Farmasoeytisk sammensetning av pinnsvinproteiner og anvendelse derav

Country Status (14)

Country Link
JP (1) JP3092706B2 (no)
KR (2) KR19990072406A (no)
CN (1) CN1228994A (no)
AT (1) ATE331533T1 (no)
AU (1) AU713568B2 (no)
CA (1) CA2260423C (no)
CZ (1) CZ33799A3 (no)
DE (1) DE69932113T2 (no)
HU (1) HUP9900251A3 (no)
IL (1) IL128329A (no)
MA (1) MA26602A1 (no)
NO (1) NO990471L (no)
NZ (1) NZ334065A (no)
SG (1) SG66504A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
KR100452752B1 (ko) * 2000-04-18 2004-10-12 주식회사 펩트론 단백질 함유 서방성 제제를 제조하는 방법 및 그 제제
KR101705323B1 (ko) * 2010-03-23 2017-02-13 코웨이 주식회사 역삼투막 방식의 정수기
CN102174794B (zh) * 2011-03-07 2012-08-15 江苏科技大学 一种六点支撑架桥作业平台自动调平系统及方法
KR102176832B1 (ko) * 2017-11-29 2020-11-10 주식회사 파이안바이오테크놀로지 헤지호그 단백질 및 생체 적합성 물질을 포함하는 미세 입자 및 이를 포함하는 탈모 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CA2260423A1 (en) 1999-08-04
HUP9900251A3 (en) 2001-01-29
NO990471D0 (no) 1999-02-01
CZ33799A3 (cs) 1999-08-11
AU713568B2 (en) 1999-12-02
IL128329A0 (en) 2000-01-31
HU9900251D0 (en) 1999-03-29
CN1228994A (zh) 1999-09-22
ATE331533T1 (de) 2006-07-15
AU1542699A (en) 1999-08-26
KR100311565B1 (ko) 2001-11-02
IL128329A (en) 2005-08-31
CA2260423C (en) 2006-06-20
HUP9900251A2 (hu) 1999-09-28
NZ334065A (en) 2000-06-23
SG66504A1 (en) 2000-07-18
JP3092706B2 (ja) 2000-09-25
JP2000119193A (ja) 2000-04-25
DE69932113T2 (de) 2007-01-25
MA26602A1 (fr) 2004-12-20
KR19990072406A (ko) 1999-09-27
KR19990072423A (ko) 1999-09-27
DE69932113D1 (de) 2006-08-10

Similar Documents

Publication Publication Date Title
Chandel et al. Self-assembly of partially alkylated dextran-graft-poly [(2-dimethylamino) ethyl methacrylate] copolymer facilitating hydrophobic/hydrophilic drug delivery and improving conetwork hydrogel properties
Haggerty et al. Biomaterials for spinal cord repair
AU3438199A (en) Controlled release of growth factors from heparin containing matrices
AU9036598A (en) Methods and compositions to prevent formation of adhesions in biological tissues
Abbah et al. In vivo bioactivity of rhBMP-2 delivered with novel polyelectrolyte complexation shells assembled on an alginate microbead core template
CA2239775A1 (en) Crosslinked polymer compositions and methods for their use
JP2003525916A5 (no)
GB2341390A (en) Composition and method for enhancing transport across biological membranes
FR2746035B1 (fr) Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
ES2181775T3 (es) Nuevos complejos de acido nucleico y de polimero, su procedimiento de preparacion y su utilizacion para la transfeccion de celulas.
WO2003068144A3 (en) Cytotoxic agents
WO2003084481A3 (en) Biological affinity based delivery systems
WO1998022097A3 (en) Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
Navarro et al. Advances in mucin mimic synthesis and applications in surface science
CA2286900A1 (en) Methods for actively binding heparin to cross-linked biological tissues
ATE285754T1 (de) Pharmazeutische zusammensetzung mit lyophilisierten lyposomen welche einen unlöslichen aktiven wirkstoff einschliessen, verfahren zu dessen herstellung
ATE482689T1 (de) Blockcopolymer-mizellenzusammensetzung mit verbesserter arzneimittelbeladungskapazität und verzögerter freisetzung
NO990471L (no) Farmasoeytisk sammensetning av pinnsvinproteiner og anvendelse derav
Rinker et al. Core-shell microparticles for protein sequestration and controlled release of a protein-laden core
BR0011554A (pt) Composições e métodos para usar intensificadores de espuma poliméricos
ATE291929T1 (de) Zusammensetzungen zur abgabe von biologischen wirkstoffen und verfahren zu ihrer herstellung
CA2210823A1 (en) Pharmaceutical compositions comprising lactobacilli suitable for trans-mucosal administration
BR9812099A (pt) Formulações para encher cápsula de gelatina de polioxialquileno glicol compreendendo copolìmeros carboxìlicos reticulados
WO1990007321A3 (en) Lymphocyte receptor homing sequences and their uses
EP0354714A3 (en) Pharmaceutical compositions containing polyaromatic compounds